• Je něco špatně v tomto záznamu ?

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

M. Svaton, M. Zemanova, P. Zemanova, J. Kultan, O. Fischer, J. Skrickova, L. Jakubikova, M. Cernovska, M. Hrnciarik, M. Jirousek, J. Krejci, D. Krejci, O. Bilek, J. Blazek, K. Hurdalkova, M. Barinova, B. Melichar,

. 2020 ; 40 (4) : 2209-2217. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023076

AIM: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. RESULTS: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. CONCLUSION: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023076
003      
CZ-PrNML
005      
20201214125233.0
007      
ta
008      
201125s2020 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.14182 $2 doi
035    __
$a (PubMed)32234916
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Svaton, Martin $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic svatonm@fnplzen.cz.
245    10
$a Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer / $c M. Svaton, M. Zemanova, P. Zemanova, J. Kultan, O. Fischer, J. Skrickova, L. Jakubikova, M. Cernovska, M. Hrnciarik, M. Jirousek, J. Krejci, D. Krejci, O. Bilek, J. Blazek, K. Hurdalkova, M. Barinova, B. Melichar,
520    9_
$a AIM: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. RESULTS: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. CONCLUSION: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.
650    _2
$a hormony kůry nadledvin $x aplikace a dávkování $7 D000305
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antibakteriální látky $x aplikace a dávkování $7 D000900
650    _2
$a antiflogistika nesteroidní $x aplikace a dávkování $7 D000894
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $7 D002289
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x aplikace a dávkování $7 D019161
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a nádory plic $x farmakoterapie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metformin $x aplikace a dávkování $7 D008687
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nivolumab $x aplikace a dávkování $7 D000077594
650    _2
$a hodnocení výsledků zdravotní péče $x metody $x statistika a číselné údaje $7 D017063
650    _2
$a probiotika $x aplikace a dávkování $7 D019936
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a inhibitory protonové pumpy $x aplikace a dávkování $7 D054328
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zemanova, Milada $u Department of Oncology, Charles University, First Faculty of Medicine in Prague, Prague, Czech Republic.
700    1_
$a Zemanova, Petra $u Department of Oncology, Charles University, First Faculty of Medicine in Prague, Prague, Czech Republic.
700    1_
$a Kultan, Juraj $u Department of Respiratory Medicine, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
700    1_
$a Fischer, Ondrej $u Department of Respiratory Medicine, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
700    1_
$a Skrickova, Jana $u Department of Respiratory Diseases and TB, Faculty of Medicine, Masaryk University Brno and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Jakubikova, Lenka $u Department of Respiratory Diseases and TB, Faculty of Medicine, Masaryk University Brno and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Cernovska, Marketa $u Department of Respiratory Medicine, First Faculty of Medicine of Charles University, Thomayer Hospital Prague, Prague, Czech Republic.
700    1_
$a Hrnciarik, Michal $u Department of Pneumology, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Jirousek, Michal $u Department of Pneumology, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Krejci, Jana $u Department of Pneumology, Charles University, Faculty of Medicine in Prague, Prague, Czech Republic.
700    1_
$a Krejci, Daniel $u Department of Pneumology, Charles University, Faculty of Medicine in Prague, Prague, Czech Republic.
700    1_
$a Bilek, Ondrej $u Department of Comprehensive Oncology, Masaryk Institute of Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Blazek, Jiri $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
700    1_
$a Hurdalkova, Karolina $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Barinova, Magda $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 40, č. 4 (2020), s. 2209-2217
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32234916 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214125232 $b ABA008
999    __
$a ok $b bmc $g 1595395 $s 1113752
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 40 $c 4 $d 2209-2217 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace